DBV Technologies SA is a clinical-stage French biopharmaceutical company headquartered in Bagneux, specializing in immunotherapy for food allergies. It pioneers the Viaskin technology, an epicutaneous patch that delivers allergens like peanut or milk proteins directly to the skin's immune cells, known as Langerhans cells, without entering the bloodstream, thereby minimizing systemic exposure risks. The lead product, Viaskin Peanut, targets peanut allergy desensitization in children and has received Fast Track designation from the US Food and Drug Administration, with successful results from the VIPES clinical trial demonstrating reduced risk of allergic reactions upon accidental exposure. Another candidate, Viaskin Milk, addresses cow's milk allergies, filling a critical gap in treatments for pediatric allergies where no effective options currently exist. Founded in 2002 by pediatric specialists, DBV Technologies SA employs around 105 people and focuses on innovative, non-invasive approaches to transform allergy management in the healthcare sector. Its E-patch further supports reliable allergy diagnostics. Operating in the biotechnology industry, it plays a key role in advancing epicutaneous immunotherapy platforms with potential broad clinical applications.